__NUXT_JSONP__("/drugs/Lutetium_Lu_177_Zalsenertant_Tetraxetan", (function(a,b,c,d){return {data:[{drug:{slug:b,emaEpar:[],fdaDrugLabel:[],id:b,nciThesaurus:{casRegistry:a,chebiId:a,chemicalFormula:a,definition:"A radioconjugate consisting of the neurotensin receptor type 1 (NTR1) antagonist, IPN01087 (3BP-227), that is linked, via the chelating agent, dodecanetetraacetic acid (DOTA), to the beta-emitting radioisotope lutetium Lu 177, with potential antineoplastic activity and imaging activity during positron emission tomography\u002Fcomputed tomography (PET\u002FCT). Upon administration, lutetium Lu 177 zalsenertant tetraxetan binds to NTR1 expressed on certain tumor cells. Upon binding and internalization, this radioconjugate specifically delivers a cytotoxic dose of beta radiation to NTR1-expressing cells. NTR1, a G-protein coupled receptor, is highly expressed in ductal pancreatic adenocarcinoma but not in normal pancreatic tissue.",fdaUniiCode:"WH9EXQ390Z",identifier:"C157630",preferredName:c,semanticType:"Pharmacologic Substance",subclassOf:["C129819","C2124"],synonyms:["177Lu-3BP-227","177Lu-DOTA-3BP-227","177Lu-DOTA-IPN01087","177Lu-IPN01087","Lutetium Lu 177 DOTA-3BP-227","Lutetium Lu 177 DOTA-IPN01087",c,"ZALSENERTANT TETRAXETAN LUTETIUM LU-177"]},dir:"\u002Fdrugs",path:"\u002Fdrugs\u002FLutetium_Lu_177_Zalsenertant_Tetraxetan",extension:".json",createdAt:d,updatedAt:d}}],fetch:{},mutations:void 0}}("","Lutetium_Lu_177_Zalsenertant_Tetraxetan","Lutetium Lu 177 Zalsenertant Tetraxetan","2021-10-30T13:34:41.863Z")));